Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
G-Tech valued at 400k after £6.7m series A, previously valued £0.
Seed PF now worth £1m alone on the book.
https://twitter.com/Bazreynolds9707/status/1277484798521544706?s=19
Message from Stephen Crowe CFO
https://twitter.com/Bazreynolds9707/status/1276459497758703616?s=19
Edison note with some updated figures based on % probability of success.
https://twitter.com/Bazreynolds9707/status/1276254244576866304?s=19
https://twitter.com/Bazreynolds9707/status/1276208859791663108?s=19
Fully funded into 2021
#NSCI No placing, 3.5m cash enough to see them well into 2021
300k Epibone shares
400k CytoVale shares
700k Drawdown facility
Glycotest 20m value
ProAxsis commercial
All funded
$pdsb ??
M Lawson 30% pushing for shareholder value through sale of assets at the right price and Divi https://t.co/neJqJ5pZcf
https://twitter.com/Bazreynolds9707/status/1276143239385448454?s=19
JBER came on to the scene on the 18th, in my opinion they took the 7.5m shares at 6p with no liquidity.
They have now pretty much sold them on, acacia might see this liquidity and look to offload the rest or manage them in new office they are setting up in Oxford, really no one knows until there is another RNS.
Massively undervalued at this price.
Clifford Press, chief executive of California-based Acacia, described the criticism as “silly”.
“There was one single price given, which we agreed for the entire portfolio,” he said. “The allocation for individual positions is a function of the tax and accounting treatment in a multi-jurisdictional trade,” he said.
Press said most of the sales had been of American companies — including Evofem Biosciences and Theravance Biopharma — and that he planned to manage the remaining investments, which include “unicorns” Oxford Nanopore and Immunocore, from a new headquarters in Oxford.
Would be great to see them get listed on an exchange.
20m contracts would pave the way.
https://twitter.com/Bazreynolds9707/status/1274739159803068418?s=19
Let's see profit booked and office in Oxford to manage the PF.
https://twitter.com/Bazreynolds9707/status/1274746315331813376?s=19
Catching up looks a very odd day must have been a large sell, same happened when it went up 600% in a few days let's hope. .
The main part of this statement is cash to last to end of 2021.
PF companies require no further funding.
Sit back and reap the rewards.
Cash on the balance sheet as at 31 December 2019 was £3.5 million (2018: £2.9 million). Cash used in operations in 2019, was £4.1 million (2018: £8.3 million). Group companies are not expected to require any further funding hereafter in 2020. ProAxsis required a short loan in January 2020 which has now been repaid. £1.2m is held in the Company, giving it and the Group enough cash to operate until the end of 2021. The cash held within subsidiary Glycotest, Inc., of £2.2m (2018: £0.1m) is not freely available for use within the wider group as it would need the consent of a 40% minority shareholder.
Officially a Covid vaccine play
NetScientific RNS to follow
https://twitter.com/Bazreynolds9707/status/1273238157652344838?s=19
Delivering another mark up on an investment and in only 2 weeks, have a look at the people running it plenty of contacts and knowledge.
PIRI will tap into that for a direct investment which should be a decent catalyst for the share price.
I am expecting a payout at some stage from the sale of Glycotest or ProAxsis.
This is where the shareholder value will come.
ProAxsis has proved its concept has a strong sales pipeline and will be profit making now. It is more appeal than most AIM companies.
Glycotest 10m funding values it at 20m before the royalties from fosun, it is carrying out 4 more trials in the US now and will launch HCC Q3.
PDSB has 3 stage 2 trials 1 under way and 2 very soon. Covid vaccine news on its way, buyout or merger possible.
All in NetScientific is funded for another year 3.5m cash in PF companies and 700k loan that it can draw on.
Mkt cap 4m cheap.